血清Cyfra21-1和SELDI技术联合检测肺鳞癌的临床意义

doi:10.3971/j.issn.1000-8578.2011.05.015

血清Cyfra21-1和SELDI技术联合检测肺鳞癌的临床意义

Clinical Significance of Cyfra21-1 Analysis Combined with SELDI-TOF-MS Technology in Lung Squamous Carcinoma

摘要

摘要: 目的探讨血清Cyfra21-1和SELDI技术联合应用在肺鳞癌患者中的诊断意义。方法应用电化学发光技术对59例病理确诊肺鳞癌患者和60例健康对照者血清进行Cyfra21-1检测，同时应用SELDI-TOF-MS和CM10 芯片检测该血清，分析两种手段的联合诊断价值。结果电化学发光法单项检测Cyfra21-1的敏感度为77.966%、特异性为96.667%。应用SELDI技术以及肺鳞癌诊断模型进行分析，敏感度为83.051%、特异性为65.385%。而联合检测的敏感度为 94.915%、特异性为95.000%。结论与单用电化学发光法检测Cyfra21-1 相比，联合SELDI技术检测更能提高肺鳞癌诊断的敏感度。联合检测的特异性也比单独使用SELDI技术有明显提高。

Abstract: ObjectiveTo study the diagnostic values of co-detections of traditional serum tumor marker(Cyfra21-1) and serum proteomic patterns by surface-enhanced laser desorption and ionization time-flight mass spectrometry (SELDI-TOF-MS) technology in patients with lung squamous carcinoma. MethodsSerum samples of 59 lung squamous carcinoma patients and 60 healthy controls were detected by electrochemiluminescence to analyze the levels of Cyfra21-1,meantime SELDI-TOF-MS and CM10-chips were employed to detect the differential expressions of proteins in serum. Combined with clinical pathological materials,the diagnostic values of two methods combination were evaluated. ResultsThe sensitivity and specificity of Cyfra21-1 detection were 77.966% and 96.667%,while SELDI-TOF-MS technology were 83.051% and 65.385%.Combined detections of two methods were 94.915% and 95.000% respectively. ConclutionThe sensitivity of co-detection was higher than that of single detection.The specificity of co-detection was higher than that of SELDI-TOF-MS technology.

HTML全文

参考文献(0)

施引文献

资源附件(0)